A single-center retrospective analysis of first-line therapy of multiple myeloma with bendamustine-bortezomib-dexamethasone

Research output: Journal article (peer-reviewed)Journal article

3 Citations (Scopus)


The aim of this retrospective study was to evaluate the efficacy and toxicity profile of bendamustine, bortezomib, and dexamethasone (BBD) combination treatment of patients with newly diagnosed multiple myeloma (MM). BBD treatment had a response rate of 80% regarding patients with ≥ partial response (PR). Median time to best response was 87.5 days and PFS was 22 months. Median of OS was not reached. PFS of non-responding patients was significantly shortened compared to those with ≥ PR. No statistically significant differences were determined concerning age (≥ vs. < 68 years) and ISS stage (ISS stage I/II vs. III). Grade 3 hematological effects and grade 3/4 non-hematological effects occurred in 20% and 35% of patients, respectively. Most pronounced hematological adverse event was leukopenia, the most severe non-hematological ones affected the cardiovascular system. In summary, BBD treatment was of acceptable efficacy in patients with newly diagnosed MM and exhibited rather low toxicity.

Original languageEnglish
Pages (from-to)2065-2070
Number of pages6
JournalLeukemia and Lymphoma
Issue number9
Publication statusPublished - 01 Sept 2016


  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Bendamustine Hydrochloride/administration & dosage
  • Biomarkers
  • Bortezomib/administration & dosage
  • Dexamethasone/administration & dosage
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma/diagnosis
  • Neoplasm Staging
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome
  • first-line therapy
  • multiple myeloma
  • Bendamustine-bortezomib-dexamethasone

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'A single-center retrospective analysis of first-line therapy of multiple myeloma with bendamustine-bortezomib-dexamethasone'. Together they form a unique fingerprint.

Cite this